The 130% premium to the undisturbed price and the all-cash nature of the deal provide a strong floor for SLN shares, which should trade near the $20.00 offer price minus deal risk. Key catalysts to monitor: (1) filing and SEC clearance of the proxy statement, (2) shareholder vote (75% of shares voted required), (3) HSR and German antitrust clearance, and (4) UK court sanction. The deal is not subject to a financing condition, reducing execution risk. Any competing bid would need to exceed $20.00/ADS to succeed.
Price Chart
Executive Summary
Silence Therapeutics plc has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash transaction valued at approximately $1.3 billion. Under the terms, Silence shareholders will receive $20.00 per ADS (or $6.6667 per ordinary share), representing a 130% premium to the closing price on October 16, 2026. The transaction is structured as a UK scheme of arrangement and is expected to close in Q1 2027, subject to shareholder and regulatory approvals.
Key Financial Metrics
Key Facts
- Merck KGaA, Darmstadt, Germany will acquire Silence Therapeutics for $20.00 per ADS ($6.6667 per ordinary share) in cash
- Equity value of approximately $1.3 billion; enterprise value of $1.1 billion
- 130% premium to Silence's closing ADS price of $8.70 on October 16, 2026; 82% premium to 30-day VWAP of $10.99
- Transaction structured as a UK scheme of arrangement under Part 26 of the Companies Act 2006
- Expected to close in Q1 2027, subject to Silence shareholder approval, UK court sanction, and regulatory clearances (HSR, German antitrust)
- Silence Board unanimously approved the transaction; certain shareholders holding ~14% voting power have entered into voting and support agreements
- Termination fee of $13 million payable by Silence in certain circumstances
- Outstanding stock options will be cashed out based on the excess of $20.00 per ADS over exercise price
Financial Impact
All-cash acquisition of Silence Therapeutics by Merck KGaA, Darmstadt, Germany for $1.3 billion equity value / $1.1 billion enterprise value. Shareholders receive $20.00 per ADS (130% premium to last close).
Risk Factors
- Shareholder vote failure (requires 75% of shares voted in favor)
- Regulatory delays or conditions from HSR or German antitrust review
- UK court declines to sanction scheme of arrangement
- Competing superior proposal could emerge despite 130% premium
- Extended timeline beyond Q1 2027 if regulatory reviews take longer
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-424695 |
| Document: d172259dex101.htm | 0001193125-26-424695 |
| Document: d172259d8k.htm | 0001193125-26-424695 |
| Document: d172259dex991.htm | 0001193125-26-424695 |
| Document: 0001193125-26-424695-index-headers.html | 0001193125-26-424695 |
| Document: 0001193125-26-424695-index.html | 0001193125-26-424695 |
| Document: 0001193125-26-424695.txt | 0001193125-26-424695 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $19.61 $19.67 | ▲ +0.31% | ▼ −0.22% | $19.78 (+0.87%) |
Oct 19, 2026 7d ago | DEFA14A | $19.58 $19.61 | ▲ +0.15% | ▼ −0.18% | $19.78 (+1.02%) |
Oct 19, 2026 7d ago | 8-K | $19.58 $19.61 | ▲ +0.15% | ▼ −0.18% | $19.78 (+1.02%) |
Oct 13, 2026 13d ago | SC 13G/A | $8.98 $9.35 | ▲ +4.12% | ▲ +3.84% | $19.78 (+120.27%) |
Oct 13, 2026 13d ago | SC 13G | $8.98 $9.35 | ▲ +4.12% | ▲ +3.84% | $19.78 (+120.27%) |
Aug 10, 2026 11w ago | 424B5 | $14.72 $13.58 | ▲ +7.74% | ▲ +8.00% | $19.78 (−34.38%) |
Aug 10, 2026 11w ago | 8-K | $15.43 $14.72 | ▼ −4.60% | ▼ −4.28% | $19.78 (+28.19%) |
Aug 10, 2026 11w ago | 8-K | $15.43 $14.72 | ▼ −4.60% | ▼ −4.28% | $19.78 (+28.19%) |
Jun 23, 2026 17w ago | 8-K | $9.16 $10.00 | ▲ +9.17% | ▲ +9.03% | $19.78 (+115.94%) |
Mar 5, 2026 33w ago | 8-K | $5.50 $6.23 | ▲ +13.27% | ▲ +14.59% | $19.78 (+259.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers